Original Research Article
The Neurofilament Heavy Chain (NfHSMI35) in the Cerebrospinal Fluid Diagnosis of Alzheimer’s DiseaseBrettschneider J.a · Petzold A.b · Schöttle D.a · Claus A.a · Riepe M.a · Tumani H.a
aDepartment of Neurology, University of Ulm, Ulm, Germany; bDepartment of Neuroimmunology, Institute of Neurology, London, UK
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background/Aims: Attempting to improve the cerebrospinal fluid (CSF) diagnosis of Alzheimer’s disease (AD), the neurofilament heavy chain isoform, NfHSMI35 was compared to other CSF markers [total tau, phospho-tau, amyloid beta 1–42 (Aβ42), the ratio of amyloid beta fragments Aβ42/Aβ40 (Aβ ratio)]. Methods: CSF levels were determined in patients with AD (n = 109), mild cognitive impairment (MCI, n = 25), frontotemporal dementia (n = 15), vascular dementia (VD, n = 41), and controls (n = 58). Results: CSF NfHSMI35 was elevated in AD and VD as compared to controls (p < 0.05). Total tau was higher in AD as compared to controls (p < 0.05). CSF phospho-tau was elevated in AD as compared to controls and VD (p < 0.05 each). CSF Aβ42 and Aβ ratios in AD were lower than in MCI and controls (p < 0.05 each). Conclusion: The diagnostic potential of NfHSMI35 is not superior to that of other CSF markers.
© 2006 S. Karger AG, Basel
- Jellinger KA: Diagnostic accuracy of Alzheimer’s disease: a clinicopathological study. Acta Neuropathol 1996;91:219–220.
- Blennow K, Vanmechelen E, Hampel H: CSF total tau, Aβ42 and phosphorylated tau as biomarkers for Alzheimer’s disease. Mol Neurobiol 2001;24:87–97.
- Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J: Neurochemical diagnosis of Alzheimer dementia by CSF Aβ42, Aβ42/40 ratio and total tau. Neurobiol Aging 2004;25:273–281.
- Andreasen N, Vanmechelen E, van De Voorde A, Davidsson P, Hesse C, Tarvonen S, Räihä I, Sourander L, Winblad B, Blennow K: Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow-up study. J Neurol Neurosurg Psychiatry 1998;64:298–305.
- Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, Pratico D, Clark CM, Coslett HB, Chatterjee A, Gee J, Trojanowski JQ, Lee VM: Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol 2005;57:721–729.
- Schoonenboom NS, Pijneburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P: Amyloid β(1–42) and phosphorylated tau in CSF as markers for early onset Alzheimer disease. Neurology 2004;62:1580–1584.
- Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H: Improved discrimination of AD patients using beta-amyloid(1–42) and tau levels in CSF. Neurology 1999;52:1555–1562.
- Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R: Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 1995;38:643–648.
- Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M: Longitudinal study of cerebrospinal fluid levels of tau, A beta1–40, and A beta 1–42(43) in Alzheimer’s disease: a study in Japan. Ann Neurol 1998;44:17–26.
- Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granerus AK, Vanderstichele H, Vanmechelen E, Blennow K: Both total and hyperphosphorylated tau are increased in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2001;70:624–630.
- Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ: A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003;278:179–190.
- Petzold A, Rejdak K, Plant GT: Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry 2004;75:1178–1180.
- Rosengren LE, Karlsson JE, Sjögren M, Blennow K, Wallin A: Neurofilament protein levels in CSF are increased in dementia. Neurology 1999;52:1090–1093.
- Sjögren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A: Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 2001;66:510–516.
- Sjögren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A: Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000;54:1960–1964.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under auspices of Department of Health and Human Services task force on Alzheimer’s disease. Neurology 1984;34:939–944.
- Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
- Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–1554.
Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–260.
- Gron G, Bittner D, Schmitz B, Wunderlich AP, Riepe MW: Subjective memory complaints: objective neural markers in patients with Alzheimer’s disease and major depressive disorder. Ann Neurol 2002;51:491–498.
- Bittner D, Gron G, Schirrmeister H, Reske SN, Riepe MW: [18F] FDG-PET in patients with Alzheimer’s disease: marker of disease spread. Dement Geriatr Cogn Disord 2005;19:24–30.
- Folstein MF, Folstein SE, McHugh PR: Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
- Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E: Standardization of measurement of beta-amyloid 1–42 in cerebrospinal fluid and plasma. Amyloid 2000;7:245–258.
- Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, Cras P: Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828–1834.
- Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49–52.
- Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, Naslund J, Muehlhauser F, Nordstedt C, Beyreuther K, Lannfelt L: Quantification of Alzheimer amyloid peptides ending at residues 40 and 42 by novel ELISA systems. Mol Med 2000;6:291–302.
- Youden WJ: Index for rating diagnostic tests. Cancer 1950;3:32–35.
Brettschneider J, Petzold A, Junker A, Tumani H: Axonal damage markers in cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite MS. Mult Scler, in press.
- Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J, Weber T, Kretzschmar HA, Poser S: Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeld-Jakob disease. Neurosci Lett 1997;225:210–212.
- Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttila T, Schapiro MB, Rapoport SI, Moller HJ, Davies P, Hampel H: Differential diagnosis of Alzheimer’s disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002;59:1267–1272.
- Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, Shizuka M, Wakabayashi K, Igeta Y, Ikeda Y, Mizushima K, Amari M, Ishiguro K, Kawarabayashi T, Harigaya Y, Okamoto K, Hirai S: Combination assay of CSF tau, Aβ 1–40 and Aβ 1–42(43) as a biochemical marker of Alzheimer’s disease. J Neurol Sci 1998;158:134–140.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.